Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for therapeutic use

a technology of cancer and compositions, applied in the direction of peptide/protein ingredients, p53 protein, peptide sources, etc., can solve the problems of significant morbidity and mortality of bladder cancer, and none of the methods tried to achieve enhanced delivery of a tumor suppressor gene to the bladder for the treatment of bladder cancer

Inactive Publication Date: 2009-02-19
CANJI
View PDF30 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009]One aspect of the invention is a method of administering a therapeutic agent to a tissue having an epithelial membrane, comprising administering a therapeutically effective amount of the therapeutic agent formulated in a buffer comprising a detergent.

Problems solved by technology

Carcinoma of the bladder represents a significant source of morbidity and mortality.
None of the methods tried to date achieve enhanced delivery of a therapeutic tumor suppressor gene to the bladder for the treatment of bladder cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for therapeutic use
  • Compositions and methods for therapeutic use
  • Compositions and methods for therapeutic use

Examples

Experimental program
Comparison scheme
Effect test

experimental examples

Example 1

Ethanol Improves Gene Transfer in the Bladder

[0039]Initial experiments have shown that several factors including virus concentration, time of administration, and volume of dosing can influence gene transfer to the bladder epithelium after intravesical administration to rats. Because increased penetration of dyes can be achieved by intravesical administration of different solvents, modification of the adenovirus formulation was also investigated as an alternative strategy to increase adenovirus transgene expression in the bladder (Monson et al. Urology 145:842-845 (1991)). The instant experiments focused on the use of ethanol to increase adenovirus transgene expression in the bladder.

[0040]Nine female buffalo rats (Harlan Sprague Dawley) were anesthetized with isoflurane and received a single intravesical administration of a human recombinant adenovirus encoding the lacZ gene (rAd-βgal). The human recombinant adenoviral vector comprising the lacZ gene (rAd-βgal) is described...

example 2

Dose-Dependent Transgene Expression in the Rat Bladder

[0042]In another experiment, 18 female Sprague-Dawley rats were anaesthetized with isoflurane and received a single 0.5 ml intravesical bolus of rAd-βgal at concentrations of 2×107, 2×108, 2×109, 2×1010, and 2×1011, PN / mL in a 22.5% (v / v) ethanol formulation. After a 45 minute incubation, the bladders were flushed with PBS, and animals were permitted to recover from anesthesia. Two days later, animals were sacrificed, and bladders were harvested, fixed, and whole organs were stained with Xgal solution to evaluate adenovirus transgene expression. β-galactosidase expression in the luminal bladder epithelium correlated with the concentration of the administered recombinant adenovirus (FIG. 3). No striking differences were observed among animals receiving 2×1010 or 2×1011 PN / mL, suggesting a saturation of transgene expression in this model: Analysis of the volume voided after instillation indicated only a minimal reduction in the inf...

example 3

ACNRB Gene Transfer in the Mouse Bladder

[0043]A pilot study was conducted to specifically evaluate expression of the RB transgene using a RT-PCR assay. The recombinant adenovirus used in this study was based on serotype 5 human adenovirus from which the viral early region 1 encoding E1a, E1b, and pIX proteins have been deleted. This adenovirus is limited to propagation in 293 cells which produce the Ad5 El gene products required for replication. Transfer plasmids encoding either full length or truncated Rb were generated from pACN (Wills et al. Cancer Gene Therapy 2:191-197 (1995)) and were, in turn, used to construct the recombinant adenoviruses. Either a full-length RB cDNA (1-928 amino acids), subcloned as a 2.8 Kb Xba I-Bam HI fragment from the plasmids pETRbc (Huang et al. Nature 350:160-162 (1991) or a truncated fragment (amino acids 381-928) subcloned as a 1.7 KB Xba 1-Bam HI cDNA fragment, was placed downstream of the CMV promoter / enhancer and the Ad 2 tripartite leader cDNA...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
volumeaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.

Description

[0001]This application is a continuation-in-part of U.S. Ser. No. 08 / 584,077, filed Jan. 8, 1996.BACKGROUND OF THE INVENTION[0002]The present invention is directed to compositions and methods of treating cancer by gene therapy using a therapeutic gene, such as a tumor suppressor gene delivered by a gene delivery system, such as a recombinant viral vector delivery system, formulated in a buffer comprising a delivery-enhancing agent. In particular, this invention relates to the delivery of a tumor suppressor gene (e.g., p53 or retinoblastoma (RB)) to cancerous epithelial tissues and organs, such as the bladder, using a recombinant adenoviral vector delivery system formulated in a buffer comprising a delivery-enhancing agent.[0003]Carcinoma of the bladder represents a significant source of morbidity and mortality. Bladder cancer ranks 10th in males and 12th in females in cancer related mortality (Cancer Facts and Figures, Amer. Can. Soc. 5:11 (1995)). Therapies available for the treatm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K48/00A61K38/02A61K31/7088A61P35/00A61K38/17A61K47/10A61K47/18C07K14/47C12N15/87
CPCA61K9/0019A61K38/1709A61K47/10A61K47/186C12N2799/022C07K14/4736C07K14/4746C12N15/87A61K48/00A61P35/00
Inventor ENGLER, HEIDRUNHUYGHE, BERNARD G.MANEVAL, DANIEL C.SHABRAM, PAUL
Owner CANJI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com